Key result
Pre-hospital POC troponin rule-out for suspected NSTE-ACS cuts 30-day costs ~€611 vs direct ED transfer.
Why the study?
Patients with suspected NSTE-ACS are routinely transferred to the ED, but whether a pre-hospital rule-out strategy using point-of-care troponin could safely identify low-risk patients and reduce healthcare costs was unknown.
Does a pre-hospital rule-out strategy using POC troponin measurement reduce healthcare costs in low-risk suspected NSTE-ACS patients?
RCT (n=863)
randomized
Yes
Does a pre-hospital rule-out strategy using POC troponin measurement reduce healthcare costs in low-risk suspected NSTE-ACS patients?
A pre-hospital rule-out strategy using POC troponin in low-risk suspected NSTE-ACS patients significantly reduces healthcare costs without compromising safety.
Answers are grounded in this paper and cite their sources.
May warrant pre-hospital POC troponin rule-out in low-risk NSTE-ACS; extends randomized evidence on safe early discharge.
AIMS: Patients with suspected non-ST-segment elevation acute coronary syndrome (NSTE-ACS) are routinely transferred to the emergency department (ED). A clinical risk score with point-of-care (POC) troponin measurement might enable ambulance paramedics to identify low-risk patients in whom ED evaluation is unnecessary. The aim was to assess safety and healthcare costs of a pre-hospital rule-out strategy using a POC troponin measurement in low-risk suspected NSTE-ACS patients. METHODS AND RESULTS: This investigator-initiated, randomized clinical trial was conducted in five ambulance regions in the Netherlands. Suspected NSTE-ACS patients with HEAR (History, ECG, Age, Risk factors) score ≤3 were randomized to pre-hospital rule-out with POC troponin measurement or direct transfer to the ED. The sample size calculation was based on the primary outcome of 30-day healthcare costs. Secondary outcome was safety, defined as 30-day major adverse cardiac events (MACE), consisting of ACS, unplanned revascularization or all-cause death. : A total of 863 participants were randomized. Healthcare costs were significantly lower in the pre-hospital strategy (€1349 ± €2051 vs. €1960 ± €1808) with a mean difference of €611 [95% confidence interval (CI): 353-869; P < 0.001]. In the total population, MACE were comparable between groups [3.9% (17/434) in pre-hospital strategy vs. 3.7% (16/429) in ED strategy; P = 0.89]. In the ruled-out ACS population, MACE were very low [0.5% (2/419) vs. 1.0% (4/417)], with a risk difference of -0.5% (95% CI -1.6%-0.7%; P = 0.41) in favour of the pre-hospital strategy. CONCLUSION: Pre-hospital rule-out of ACS with a POC troponin measurement in low-risk patients significantly reduces healthcare costs while incidence of MACE was low in both strategies. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT05466591 and International Clinical Trials Registry Platform id NTR 7346.
No takes yet. Share an insight, caveat, or question.
Camaro et al. (2023) conducted an RCT in Suspected non-ST-segment elevation acute coronary syndrome (NSTE-ACS) (n=863). Pre-hospital rule-out with point-of-care (POC) troponin measurement vs. Direct transfer to the emergency department (ED) was evaluated on 30-day healthcare costs (Mean difference €611, 95% CI 353-869, p=<0.001). Pre-hospital rule-out of suspected NSTE-ACS using POC troponin reduced 30-day healthcare costs compared to direct ED transfer.
Synapse has enriched 10 related papers. Consider them for comparative context: